ETON - Eton Pharmaceuticals, Inc.
IEX Last Trade
12.8
0.120 0.938%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:22:05 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$12.68
0.12
0.95%
Fundamental analysis
22%
Profitability
8%
Dept financing
28%
Liquidity
75%
Performance
22%
Performance
5 Days
0.72%
1 Month
5.24%
3 Months
127.29%
6 Months
285.98%
1 Year
175.82%
2 Year
322.00%
Key data
Stock price
$12.80
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.20 - $13.98
52 WEEK CHANGE
$172.26
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Sean E. Brynjelsen
Region: US
Website: etonpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: etonpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eton Pharmaceuticals, Inc. focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting from vasodilation in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age.
Recent news